<DOC>
	<DOCNO>NCT01024920</DOCNO>
	<brief_summary>Compare safety efficacy BIBF 1120 versus sunitinib patient advance RCC investigate effect BIBF 1120 heart rate ( HR ) correct QT interval ( QTcF ) .</brief_summary>
	<brief_title>Compare Safety Efficacy BIBF 1120 Versus Sunitinib .</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients unresectable metastatic Renal Cell Cancer , receive previous systemic anticancer treatment . 2 . Histologicalconfirmed diagnosis renal cell cancer clear cell component . 3 . Acceptable renal , liver , cardiovascular , bone marrow function allow sunitinib/BIBF 1120 treatment . Exclusion criterion : 1 . Patients unable tolerate Sunitinib/BIBF 1120 treatment 2 . Treatment investigational drug participation another clinical study within past 4 week start therapy concomitantly study . 3 . Patients unable comply 1199.26 protocol . 4 . Pregnancy breast feed . 5 . Active alcohol drug abuse . 6 . Women child bear potential , men able father child , unwilling use medically acceptable form contraception study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>